Approval · Notice of Compliance 13656 · 2012
HALAVEN: Notice of Compliance 13656
Issued September 7, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13656
- Date
- September 7, 2012
- Company
- Eisai LimitedWoodcliff Lake, New Jersey, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate drug product manufacturing facility involved in the production and testing (release and stability) of a sterile drug product
- Therapeutic class
- Antineoplastic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HALAVEN | Not yet assigned | — |
Medicinal ingredients
- ERIBULIN MESYLATE 0.5 MG per ML